The loss of DUSP1 expression is a characteristic of TSCs and is associated with the expression of tumor stem cell markers (ABCG2, NANOG, SOX2, PROM1, and L1CAM) in situ, which indicates that DUSP1 participates in the survival of these therapeutically resistant patients associated with GBM.110. This evidence concerns the gene DUSP1 and neoplasm.